Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to High-Intensity Statin Therapy

NCT04753606 is registered in ClinicalTrials.gov with NewAmsterdam Pharma as lead sponsor.

NCT NCT04753606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04753606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to High-Intensity Statin Therapy
Lead sponsor
NewAmsterdam Pharma
Phase
Phase 2
Overall status
Completed
Start date
February 18, 2021
Completion date
August 30, 2021
Enrollment
120 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemias, high cholesterol, hypercholesterolemia